[go: up one dir, main page]

DE69431747D1 - Hochlösliche multikomponenten-inklusionskomplexe, welche ein basisches arzneimittel, eine säure und ein zyklodextrin enthalten - Google Patents

Hochlösliche multikomponenten-inklusionskomplexe, welche ein basisches arzneimittel, eine säure und ein zyklodextrin enthalten

Info

Publication number
DE69431747D1
DE69431747D1 DE69431747T DE69431747T DE69431747D1 DE 69431747 D1 DE69431747 D1 DE 69431747D1 DE 69431747 T DE69431747 T DE 69431747T DE 69431747 T DE69431747 T DE 69431747T DE 69431747 D1 DE69431747 D1 DE 69431747D1
Authority
DE
Germany
Prior art keywords
acid
extrin
cyclode
medicinal product
highly soluble
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69431747T
Other languages
English (en)
Inventor
Paolo Chiesi
Paolo Ventura
Massimo Pasini
Joesef Szejtli
Maria Vikmon
Enrico Redenti
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chiesi Farmaceutici SpA
Original Assignee
Chiesi Farmaceutici SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chiesi Farmaceutici SpA filed Critical Chiesi Farmaceutici SpA
Application granted granted Critical
Publication of DE69431747D1 publication Critical patent/DE69431747D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6949—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes
    • A61K47/6951—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit inclusion complexes, e.g. clathrates, cavitates or fullerenes using cyclodextrin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B82—NANOTECHNOLOGY
    • B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
    • B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nanotechnology (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Biophysics (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE69431747T 1993-01-29 1994-01-26 Hochlösliche multikomponenten-inklusionskomplexe, welche ein basisches arzneimittel, eine säure und ein zyklodextrin enthalten Expired - Lifetime DE69431747D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ITMI930141A IT1263831B (it) 1993-01-29 1993-01-29 Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo basico, un acido ed una ciclodestrina
PCT/EP1994/000205 WO1994016733A1 (en) 1993-01-29 1994-01-26 Highly soluble multicomponent inclusion complexes containing a base type drug, an acid and a cyclodextrin

Publications (1)

Publication Number Publication Date
DE69431747D1 true DE69431747D1 (de) 2003-01-02

Family

ID=11364792

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69431747T Expired - Lifetime DE69431747D1 (de) 1993-01-29 1994-01-26 Hochlösliche multikomponenten-inklusionskomplexe, welche ein basisches arzneimittel, eine säure und ein zyklodextrin enthalten

Country Status (18)

Country Link
US (1) US5855916A (de)
EP (1) EP0681481B1 (de)
JP (1) JPH08508711A (de)
KR (1) KR960700074A (de)
AT (1) ATE228013T1 (de)
AU (1) AU691115B2 (de)
BR (1) BR9406779A (de)
CA (1) CA2154874A1 (de)
CZ (1) CZ284606B6 (de)
DE (1) DE69431747D1 (de)
FI (1) FI953590A7 (de)
HU (1) HU218796B (de)
IL (1) IL108460A (de)
IT (1) IT1263831B (de)
NO (1) NO952981L (de)
NZ (1) NZ261115A (de)
WO (1) WO1994016733A1 (de)
ZA (1) ZA94572B (de)

Families Citing this family (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids
AUPM456894A0 (en) * 1994-03-18 1994-04-14 Glyzinc Pharmaceuticals Limited Treatment for gastric disorders
IT1269578B (it) * 1994-04-22 1997-04-08 Chiesi Farma Spa Complessi di inclusione multicomponente ad elevata solubilita' costituiti da un farmaco di tipo acido, una ciclodestrina e una base.
US5750147A (en) * 1995-06-07 1998-05-12 Emisphere Technologies, Inc. Method of solubilizing and encapsulating itraconazole
UA57734C2 (uk) 1996-05-07 2003-07-15 Пфайзер Інк. Комплекси включення арилгетероциклічних солей
IL127955A0 (en) 1996-07-11 1999-11-30 Farmarc Nederland Bv Pharmaceutical composition containing acid addition salt of basic drug
GB9711643D0 (en) * 1997-06-05 1997-07-30 Janssen Pharmaceutica Nv Glass thermoplastic systems
KR19990001564A (ko) * 1997-06-16 1999-01-15 유충식 용해도를 개선한 아졸계 항진균제 및 이를 함유하는 제제
ES2174388T3 (es) * 1997-06-27 2002-11-01 Akzo Nobel Nv Solucion liquida de medicamento para administracion oral.
US6077871A (en) * 1997-11-26 2000-06-20 Pfizer Inc. Droloxifene pharmaceutical compositions
DK172860B1 (da) * 1998-03-25 1999-08-16 Pharmacosmos Holding As Jerndextranforbindelse til anvendelse som komponent i et terapeutisk middel til forebyggelse af eller behandling af jernman
JP2000080123A (ja) * 1998-09-03 2000-03-21 Toagosei Co Ltd シアノアクリレート用硬化促進剤
GB9822170D0 (en) * 1998-10-13 1998-12-02 Danbioyst Uk Ltd Novel formulations of fexofenadine
FI982733L (fi) 1998-12-17 2000-06-18 Orion Yhtymae Oyj Trifenyylietyleeniantiestrogeenien liukoisia koostumuksia
FI109332B (fi) 1998-12-17 2002-07-15 Orion Yhtymae Oyj Toremifeenin liukoisia koostumuksia
US6740639B1 (en) * 2000-03-29 2004-05-25 Council Of Scientific & Industrial Research Inclusion complees of a high potent opioid peptide, pharmaceutical compositions and method of treatment
GB0015239D0 (en) * 2000-06-21 2000-08-16 Biochemie Gmbh Organic compounds
US6663897B2 (en) 2001-02-06 2003-12-16 Dsm Ip Assets B.V. Oral itraconazole formulations and methods of making the same
JP2003063965A (ja) * 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
WO2003052117A2 (en) * 2001-09-19 2003-06-26 Massachusetts Institute Of Technology Methods and products related to non-viral transfection
US7927613B2 (en) 2002-02-15 2011-04-19 University Of South Florida Pharmaceutical co-crystal compositions
US7446107B2 (en) 2002-02-15 2008-11-04 Transform Pharmaceuticals, Inc. Crystalline forms of conazoles and methods of making and using the same
US7790905B2 (en) 2002-02-15 2010-09-07 Mcneil-Ppc, Inc. Pharmaceutical propylene glycol solvate compositions
CA2477923C (en) 2002-03-01 2021-02-23 University Of South Florida Multiple-component solid phases containing at least one active pharmaceutical ingredient
AU2003243354A1 (en) 2002-05-31 2003-12-19 Transform Pharmaceuticals, Inc. Novel conazole crystalline forms and related processes, pharmaceutical compositions and methods
AU2003243699B2 (en) 2002-06-21 2009-01-15 Transform Pharmaceuticals, Inc. Pharmaceutical compositions with improved dissolution
HRP20050149B1 (hr) 2002-08-20 2014-09-12 Otsuka Pharmaceutical Co., Ltd. Formulacija aripiprazol kompleksa i postupak
US7648678B2 (en) 2002-12-20 2010-01-19 Dako Denmark A/S Method and system for pretreatment of tissue slides
US8183290B2 (en) 2002-12-30 2012-05-22 Mcneil-Ppc, Inc. Pharmaceutically acceptable propylene glycol solvate of naproxen
US20050085446A1 (en) * 2003-04-14 2005-04-21 Babu M.K. M. Fluoroquinolone formulations and methods of making and using the same
US7157446B2 (en) * 2003-05-02 2007-01-02 Bristol Myers Squibb Company Complex of ras-farnesyltransferase inhibitor, a cyclodextrin, and ethanol
CN1515260B (zh) * 2003-06-26 2010-05-05 沈阳药科大学 含hpcd的桂利嗪粉针剂和其固体制剂及其制备方法
RU2356909C2 (ru) 2003-11-13 2009-05-27 Ханми Фарм. Инд. Ко., Лтд. Белковый комплекс, полученный с использованием фрагмента иммуноглобулина, и способ получения такого комплекса
US20070020299A1 (en) 2003-12-31 2007-01-25 Pipkin James D Inhalant formulation containing sulfoalkyl ether cyclodextrin and corticosteroid
EP1570862A1 (de) * 2004-02-25 2005-09-07 JPM - The Jordanian Pharmaceutical Manufacturing Co. Ltd. Hochlösliche binäre Cyclodextrineinschlusskomplexe
WO2005092884A1 (en) * 2004-02-26 2005-10-06 Transform Pharmaceuticals, Inc. Novel crystalline forms of conazoles and methods of making and using the same
CN1997372B (zh) * 2004-06-24 2010-06-02 西梯茜生命工学股份有限公司 包含依他康那唑的固态分散剂的制造方法及其医药组成物
US20060105992A1 (en) * 2004-11-08 2006-05-18 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and selective estrogen receptor modulator compounds
WO2006052921A2 (en) * 2004-11-08 2006-05-18 Eastman Chemical Company Cyclodextrin solubilizers for liquid and semi-solid formulations
DE102005041860A1 (de) * 2005-09-02 2007-03-08 Schering Ag Nanopartikulärer Einschluss- und Ladungskomplex für pharmazeutische Formulierungen
US20070082870A1 (en) * 2005-10-11 2007-04-12 Buchanan Charles M Pharmaceutical formulations of cyclodextrins and antifungal azole compounds
US12370352B2 (en) 2007-06-28 2025-07-29 Cydex Pharmaceuticals, Inc. Nasal and ophthalmic delivery of aqueous corticosteroid solutions
WO2009099625A2 (en) * 2008-02-08 2009-08-13 The Board Of Regents Of The University Of Texas System Cyclopamine tartrate salt and uses thereof
CN101314045B (zh) * 2008-05-09 2013-01-23 沈阳药科大学 桂利嗪的磺丁基醚-β-环糊精包合物及其制剂和制备方法
BRPI0913939A2 (pt) 2008-07-03 2016-04-26 Univ Virginia Patent Found dose unitária de apadenoson
EP2331092B1 (de) 2008-08-21 2014-03-19 The Johns Hopkins University Verfahren und zusammensetzungen zur verabreichung von 3-halopyruvat und verwandten verbindungen zur behandlung von krebs
US11020363B2 (en) 2009-05-29 2021-06-01 Cydex Pharmaceuticals, Inc. Injectable nitrogen mustard compositions comprising a cyclodextrin derivative and methods of making and using the same
AU2010253905B2 (en) 2009-05-29 2014-10-02 Cydex Pharmaceuticals, Inc. Injectable melphalan compositions comprising a cyclodextrin derivative and methods of making and using the same
JP5803150B2 (ja) * 2011-03-02 2015-11-04 三菱瓦斯化学株式会社 ピロロキノリンキノンーシクロデキストリン包接体
CN105744944B (zh) 2013-09-09 2020-07-07 卡尼姆盖德治疗学公司 免疫系统调节器
CN115054698B (zh) * 2014-01-14 2024-11-08 约翰斯·霍普金斯大学 包封选择性atp抑制剂的环糊精组合物及其应用
WO2016072985A1 (en) 2014-11-05 2016-05-12 Halliburton Energy Services, Inc. Delayed acid breaker systems for filtercakes
ES2853582T3 (es) 2015-03-06 2021-09-16 Canimguide Therapeutics Ab Moduladores del sistema inmune y composiciones
CN106539752B (zh) * 2015-09-18 2019-10-29 成都康弘药业集团股份有限公司 一种含有阿立哌唑的口服溶液及其制备方法
EP3370712B1 (de) 2015-11-06 2025-02-19 The Johns Hopkins University 3-brompyruvat zur behandlung von leberfibrose
EP4149427A1 (de) 2020-06-11 2023-03-22 Sentiss Pharma Private Limited Ophthalmische zusammensetzungen mit einer kombination aus einem antibakteriellen fluorchinolonmittel und einem entzündungshemmenden mittel
KR102356618B1 (ko) * 2021-11-17 2022-02-08 명지대학교 산학협력단 신규 포접복합체 및 이의 용도

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU182217B (en) * 1980-10-17 1983-12-28 Chinoin Gyogyszer Es Vegyeszet Process for producing inclusive complexes of cyclodextrines and strong inorganic oxyacids
JPS60185772A (ja) * 1984-03-05 1985-09-21 Mitsui Pharmaceut Inc 安定なカルモフ−ル−β−シクロデキストリンの包接化合物
US5091171B2 (en) * 1986-12-23 1997-07-15 Tristrata Inc Amphoteric compositions and polymeric forms of alpha hydroxyacids and their therapeutic use
JP2571199B2 (ja) * 1987-11-25 1997-01-16 塩水港精糖株式会社 溶解性の高いサイクロデキストリンの製造方法
US5646131A (en) * 1994-02-22 1997-07-08 The Arab Company For Drug Industries And Medical Applicances (Acdima) Method for solubilizing drugs using cyclodextrins and carboxylic acids

Also Published As

Publication number Publication date
HU218796B (hu) 2000-12-28
IT1263831B (it) 1996-09-04
ITMI930141A0 (it) 1993-01-29
HUT72500A (en) 1996-05-28
FI953590L (fi) 1995-09-14
IL108460A0 (en) 1994-04-12
CA2154874A1 (en) 1994-08-04
WO1994016733A1 (en) 1994-08-04
NO952981D0 (no) 1995-07-27
JPH08508711A (ja) 1996-09-17
EP0681481B1 (de) 2002-11-20
ATE228013T1 (de) 2002-12-15
ZA94572B (en) 1994-09-13
BR9406779A (pt) 1996-02-06
CZ194395A3 (en) 1996-01-17
NO952981L (no) 1995-07-27
EP0681481A1 (de) 1995-11-15
FI953590A7 (fi) 1995-09-14
AU5971094A (en) 1994-08-15
KR960700074A (ko) 1996-01-19
CZ284606B6 (cs) 1999-01-13
AU691115B2 (en) 1998-05-07
HU9502251D0 (en) 1995-09-28
FI953590A0 (fi) 1995-07-27
US5855916A (en) 1999-01-05
NZ261115A (en) 1996-11-26
ITMI930141A1 (it) 1994-07-30
IL108460A (en) 1999-01-26

Similar Documents

Publication Publication Date Title
DE69431747D1 (de) Hochlösliche multikomponenten-inklusionskomplexe, welche ein basisches arzneimittel, eine säure und ein zyklodextrin enthalten
HUP9800688A2 (hu) Gamma-ciklodextrin és retinol, ill. retinolszármazékok komplexei, eljárás ezek előállítására és ezeket tartalmazó kozmetikai és gyógyszerkészítmények
DE69422921D1 (de) Vorrichtung zum verabreichen von pharmazeutischen substanzen
ATE218870T1 (de) Verbindungen von wirkstoffen, welche klopidogrel und antithrombotische mittel enthalten
NL300109I1 (nl) Kristalmodificatie van CDCH, werkwijze voor de bereiding ervan en van farmaceutische preparaten die deze modificaties bevatten.
DE59409568D1 (de) Wirkstoffe und gas enthaltende mikropartikel
SE9302395D0 (sv) New pharmaceutical formulation
DE69222950D1 (de) Darmlösliche oral verabreichbare arzneimittel welche säurelabile verbindungen enthalten
GEP20012375B (en) Isothiazolones, Pharmaceutical Composition on Their Basis and Method for Obtaining the Same
NO954320D0 (no) Lyosfærer omfattende gonadotropin
ATE145649T1 (de) Kardioaktive 17-aryl und 17-heterozyklyl-14 beta- 5alpha-androstane, androstene und androstadiene, ein verfahren zu ihrer herstellung und pharmazeutische präperate davon
HUT68239A (en) Process for producing inclusion complexes of nimesulide alkali salts with cyclodextrins or cyclodextrin derivatives and pharmaceutical preparations containing them
DE69518070D1 (de) Mehrfachkomponenten-inklusionskomplexe enthaltend einen sauren arzneistoff, ein zyklodextrin und eine base
BR9810267A (pt) Preparados de combinações farmacêuticas, processo para a produção dos mesmos, utilização de preparados de eritropoietina e embalagem unitária farmacêutica
ATE145380T1 (de) Spender für feste arzneimittel
ATE150004T1 (de) Tilidin-dihydrogenorthophosphat, verfahren zu dessen herstellung und dieses enthaltende pharmazeutische zubereitungen
GR3021231T3 (en) Process for preparing stable hydrophilic or ambiphic cream preparations containing vesicular composnents and their use
GEP20012518B (en) Novel Erythromycin Derivatives, Method for Their Preparation and Their Use as Medicine
ATE223717T1 (de) Topisch anzuwendendes abschäumendes arzneimittel zur behandlung von durch pityrosporum ovale verursachten hauterkrankungen
ATE155136T1 (de) Neue bishispidinderivate, verfahren zu ihrer herstellung und diese verbindungen enthaltende arzneimittel
ATE106883T1 (de) Azelastin-embonat, verfahren zu seiner herstellung und pharmazeutische zubereitungen, die als wirkstoff azelastin-embonat enthalten.
HUP9900796A2 (hu) Szubsztituált pirrolok karbamidszármazékainak alkalmazása sclerosis multiplex kezelésére alkalmas gyógyszerkészítmények előállítására
FR2701397B1 (fr) Produit pour l'administration topique de substances médicamenteuses ou cosmétologiques.
DE69228970D1 (de) Dithranol enthaltendes Arzneimittel zur topischen Anwendung sowie Herstellungsverfahren
DE69215511D1 (de) Gem-diphosphonsäure-nitrosocarbamoylderivate, verfahren zu deren herstellung und sie enthaltende pharmazeutische zubereitungen

Legal Events

Date Code Title Description
8332 No legal effect for de